A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata

Brett King; Xingqi Zhang; Walter Gubelin Harcha; Jacek C. Szepietowski; Jerry Shapiro; Charles Lynde; Natasha A. Mesinkovska; Samuel H. Zwillich; Lynne Napatalung; Dalia Wajsbrot; Rana Fayyad; Amy Freyman; Debanjali Mitra; Vivek Purohit; Rodney Sinclair; Robert Wolk

doi:10.2217/imt-2023-0069

A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata

Brett King, Xingqi Zhang, Walter Gubelin Harcha, Jacek C. Szepietowski, Jerry Shapiro, Charles Lynde, Natasha A. Mesinkovska, Samuel H. Zwillich, Lynne Napatalung, Dalia Wajsbrot, Rana Fayyad, Amy Freyman, Debanjali Mitra, Vivek Purohit, Rodney Sinclair, Robert Wolk

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

What is this summary about? This is a summary of the results of the ALLEGRO phase 2b/3 clinical trial, originally published in The Lancet. ALLEGRO-2b/3 looked at how well and safely the study medicine, ritlecitinib, works in treating people with alopecia areata ('AA' for short). The immune system protects your body from outside invaders such as bacteria and viruses. AA is an autoimmune disease, meaning a disease in which one's immune system attacks healthy cells of the body by mistake. In AA, the immune system attacks hair follicles, causing hair to fall out. AA causes hair loss ranging from small bald patches to complete hair loss on the scalp, face, and/or body. Ritlecitinib is a medicine taken as a pill every day, by mouth, that is approved for the treatment of severe AA. It blocks processes that are known to play a role in causing hair loss in patients with AA. What were the results of the study? Adults and adolescents (12 years and older) took part in the ALLEGRO-2b/3 study. They either took ritlecitinib for 48 weeks or took a placebo (a pill with no medicine) for 24 weeks. Participants taking placebo later switched to taking ritlecitinib for 24 weeks. The study showed that participants taking ritlecitinib had more hair regrowth on their scalp after 24 weeks than those taking the placebo. Hair regrowth was also seen on the eyebrows and eyelashes in participants taking ritlecitinib. Hair regrowth continued to improve to week 48 with continued ritlecitinib treatment. In addition, more participants taking ritlecitinib reported that their AA had 'moderately' or 'greatly' improved after 24 weeks than those taking the placebo. Similar numbers of participants taking ritlecitinib or placebo had side effects after 24 weeks. Most side effects were mild or moderate. What do the results of the study mean? Ritlecitinib was an effective and well-tolerated treatment over 48 weeks for people with AA. Clinical Trial Registration: NCT03732807 (phase 2b/3 ALLEGRO study) </sec.

Original language	English
Pages (from-to)	1093-1103
Number of pages	11
Journal	Immunotherapy
Volume	15
Issue number	14
DOIs	https://doi.org/10.2217/imt-2023-0069
State	Published - 1 Oct 2023

Keywords

adolescents
alopecia areata
hair loss
ritlecitinib

Access to Document

10.2217/imt-2023-0069

Cite this

King, B., Zhang, X., Harcha, W. G., Szepietowski, J. C., Shapiro, J., Lynde, C., Mesinkovska, N. A., Zwillich, S. H., Napatalung, L., Wajsbrot, D., Fayyad, R., Freyman, A., Mitra, D., Purohit, V., Sinclair, R., & Wolk, R. (2023). A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata. Immunotherapy, 15(14), 1093-1103. https://doi.org/10.2217/imt-2023-0069

@article{13a1db2374c948f2a5aa2ec94fbfe443,

title = "A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata",

abstract = "What is this summary about? This is a summary of the results of the ALLEGRO phase 2b/3 clinical trial, originally published in The Lancet. ALLEGRO-2b/3 looked at how well and safely the study medicine, ritlecitinib, works in treating people with alopecia areata ('AA' for short). The immune system protects your body from outside invaders such as bacteria and viruses. AA is an autoimmune disease, meaning a disease in which one's immune system attacks healthy cells of the body by mistake. In AA, the immune system attacks hair follicles, causing hair to fall out. AA causes hair loss ranging from small bald patches to complete hair loss on the scalp, face, and/or body. Ritlecitinib is a medicine taken as a pill every day, by mouth, that is approved for the treatment of severe AA. It blocks processes that are known to play a role in causing hair loss in patients with AA. What were the results of the study? Adults and adolescents (12 years and older) took part in the ALLEGRO-2b/3 study. They either took ritlecitinib for 48 weeks or took a placebo (a pill with no medicine) for 24 weeks. Participants taking placebo later switched to taking ritlecitinib for 24 weeks. The study showed that participants taking ritlecitinib had more hair regrowth on their scalp after 24 weeks than those taking the placebo. Hair regrowth was also seen on the eyebrows and eyelashes in participants taking ritlecitinib. Hair regrowth continued to improve to week 48 with continued ritlecitinib treatment. In addition, more participants taking ritlecitinib reported that their AA had 'moderately' or 'greatly' improved after 24 weeks than those taking the placebo. Similar numbers of participants taking ritlecitinib or placebo had side effects after 24 weeks. Most side effects were mild or moderate. What do the results of the study mean? Ritlecitinib was an effective and well-tolerated treatment over 48 weeks for people with AA. Clinical Trial Registration: NCT03732807 (phase 2b/3 ALLEGRO study) ",

keywords = "adolescents, alopecia areata, hair loss, ritlecitinib",

author = "Brett King and Xingqi Zhang and Harcha, {Walter Gubelin} and Szepietowski, {Jacek C.} and Jerry Shapiro and Charles Lynde and Mesinkovska, {Natasha A.} and Zwillich, {Samuel H.} and Lynne Napatalung and Dalia Wajsbrot and Rana Fayyad and Amy Freyman and Debanjali Mitra and Vivek Purohit and Rodney Sinclair and Robert Wolk",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors.",

year = "2023",

month = oct,

day = "1",

doi = "10.2217/imt-2023-0069",

language = "English",

volume = "15",

pages = "1093--1103",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "14",

}

King, B, Zhang, X, Harcha, WG, Szepietowski, JC, Shapiro, J, Lynde, C, Mesinkovska, NA, Zwillich, SH, Napatalung, L, Wajsbrot, D, Fayyad, R, Freyman, A, Mitra, D, Purohit, V, Sinclair, R & Wolk, R 2023, 'A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata', Immunotherapy, vol. 15, no. 14, pp. 1093-1103. https://doi.org/10.2217/imt-2023-0069

TY - JOUR

T1 - A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata

AU - King, Brett

AU - Zhang, Xingqi

AU - Harcha, Walter Gubelin

AU - Szepietowski, Jacek C.

AU - Shapiro, Jerry

AU - Lynde, Charles

AU - Mesinkovska, Natasha A.

AU - Zwillich, Samuel H.

AU - Napatalung, Lynne

AU - Wajsbrot, Dalia

AU - Fayyad, Rana

AU - Freyman, Amy

AU - Mitra, Debanjali

AU - Purohit, Vivek

AU - Sinclair, Rodney

AU - Wolk, Robert

PY - 2023/10/1

Y1 - 2023/10/1

N2 - What is this summary about? This is a summary of the results of the ALLEGRO phase 2b/3 clinical trial, originally published in The Lancet. ALLEGRO-2b/3 looked at how well and safely the study medicine, ritlecitinib, works in treating people with alopecia areata ('AA' for short). The immune system protects your body from outside invaders such as bacteria and viruses. AA is an autoimmune disease, meaning a disease in which one's immune system attacks healthy cells of the body by mistake. In AA, the immune system attacks hair follicles, causing hair to fall out. AA causes hair loss ranging from small bald patches to complete hair loss on the scalp, face, and/or body. Ritlecitinib is a medicine taken as a pill every day, by mouth, that is approved for the treatment of severe AA. It blocks processes that are known to play a role in causing hair loss in patients with AA. What were the results of the study? Adults and adolescents (12 years and older) took part in the ALLEGRO-2b/3 study. They either took ritlecitinib for 48 weeks or took a placebo (a pill with no medicine) for 24 weeks. Participants taking placebo later switched to taking ritlecitinib for 24 weeks. The study showed that participants taking ritlecitinib had more hair regrowth on their scalp after 24 weeks than those taking the placebo. Hair regrowth was also seen on the eyebrows and eyelashes in participants taking ritlecitinib. Hair regrowth continued to improve to week 48 with continued ritlecitinib treatment. In addition, more participants taking ritlecitinib reported that their AA had 'moderately' or 'greatly' improved after 24 weeks than those taking the placebo. Similar numbers of participants taking ritlecitinib or placebo had side effects after 24 weeks. Most side effects were mild or moderate. What do the results of the study mean? Ritlecitinib was an effective and well-tolerated treatment over 48 weeks for people with AA. Clinical Trial Registration: NCT03732807 (phase 2b/3 ALLEGRO study)

AB - What is this summary about? This is a summary of the results of the ALLEGRO phase 2b/3 clinical trial, originally published in The Lancet. ALLEGRO-2b/3 looked at how well and safely the study medicine, ritlecitinib, works in treating people with alopecia areata ('AA' for short). The immune system protects your body from outside invaders such as bacteria and viruses. AA is an autoimmune disease, meaning a disease in which one's immune system attacks healthy cells of the body by mistake. In AA, the immune system attacks hair follicles, causing hair to fall out. AA causes hair loss ranging from small bald patches to complete hair loss on the scalp, face, and/or body. Ritlecitinib is a medicine taken as a pill every day, by mouth, that is approved for the treatment of severe AA. It blocks processes that are known to play a role in causing hair loss in patients with AA. What were the results of the study? Adults and adolescents (12 years and older) took part in the ALLEGRO-2b/3 study. They either took ritlecitinib for 48 weeks or took a placebo (a pill with no medicine) for 24 weeks. Participants taking placebo later switched to taking ritlecitinib for 24 weeks. The study showed that participants taking ritlecitinib had more hair regrowth on their scalp after 24 weeks than those taking the placebo. Hair regrowth was also seen on the eyebrows and eyelashes in participants taking ritlecitinib. Hair regrowth continued to improve to week 48 with continued ritlecitinib treatment. In addition, more participants taking ritlecitinib reported that their AA had 'moderately' or 'greatly' improved after 24 weeks than those taking the placebo. Similar numbers of participants taking ritlecitinib or placebo had side effects after 24 weeks. Most side effects were mild or moderate. What do the results of the study mean? Ritlecitinib was an effective and well-tolerated treatment over 48 weeks for people with AA. Clinical Trial Registration: NCT03732807 (phase 2b/3 ALLEGRO study)

KW - adolescents

KW - alopecia areata

KW - hair loss

KW - ritlecitinib

UR - http://www.scopus.com/inward/record.url?scp=85169299107&partnerID=8YFLogxK

U2 - 10.2217/imt-2023-0069

DO - 10.2217/imt-2023-0069

M3 - Review article

C2 - 37403610

AN - SCOPUS:85169299107

SN - 1750-743X

VL - 15

SP - 1093

EP - 1103

JO - Immunotherapy

JF - Immunotherapy

IS - 14

ER -

A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata

Abstract

Keywords

Access to Document

Fingerprint

Cite this